Short Interest in Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Expands By 26.8%

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 8,048,300 shares, a growth of 26.8% from the October 31st total of 6,347,300 shares. Based on an average trading volume of 5,400 shares, the days-to-cover ratio is currently 1,490.4 days.

Sino Biopharmaceutical Stock Performance

SBMFF remained flat at $0.42 during mid-day trading on Friday. 100 shares of the company’s stock were exchanged, compared to its average volume of 1,985. The stock’s 50-day moving average is $0.45 and its two-hundred day moving average is $0.39. Sino Biopharmaceutical has a 1-year low of $0.31 and a 1-year high of $0.47.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.